The proMMP-2 activation rate in patients with chronic viral liver disease

Clinica Chimica Acta

Volumn 324, Issue 1-2, 2002, Pages 99-103

  Murawaki, Yoshikazu ^a   Ikuta, Yujiro ^a   Koda, Masahiko ^a   Okamoto, Kinya ^a   Mimura, Kenichi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Active MMP 2; Liver disease; proMMP 2; proMMP 2 activation; TIMP 2

Indexed keywords

METALLOPROTEINASE; PROMATRIX METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; SERUM; VIRUS HEPATITIS;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENZYME ACTIVATION; ENZYME PRECURSORS; FEMALE; GELATINASES; HUMANS; KINETICS; LIVER DISEASES; MALE; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MIDDLE AGED; VIRUS DISEASES;

EID: 0036774079     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00239-5     Document Type: Article

References (20)

1. Arthur M.J.P. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol.: Gasterointest. Liver Physiol. 279:2000;G245-G249.
2. Murawaki Y., Ikuta Y., Idobe Y., Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J. Gastroenterol. Hepatol. 14:1999;138-145.
3. Murawaki Y., Ikuta Y., Okamoto K., Kawasaki H. Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease. J. Hepatol. 31:1999;474-481.
4. Ebata M., Fukuda Y., Nakano I., Katano Y., Fujimoto N., Hayakawa T. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver. 17:1997;293-299.
5. Murawaki Y., Yamada S., Ikuta Y., Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J. Hepatol. 30:1999;1090-1098.
6. Seiki M. Membrane-type matrix metalloproteinases. APMIS. 107:1999;137-143.
7. Wang Z., Juttermann R., Soloway P.D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 275:2000;26411-26415.
8. Caterina J.J., Yamada S., Caterina N.C.M., Longenecker G., Holmbäk K., Shi J.et al. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2 (TIMP-2) gene alters proMMP-2 activation. J. Biol. Chem. 275:2000;26416-26422.
9. Toth M., Bernardo M.M., Gervasi D.C., Soloway P.D., Wang Z., Bigg H.F.et al. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors, but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of proMMP-2. J. Biol. Chem. 275:2000;41415-41423.
10. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N.et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology. 1:1981;431-435.
11. Verheijen J.H., Nieuwenbroek N.M.E., Beekman B., Hanemaaijer R., Verspaget H.W., Ronday H.K.et al. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem. J. 323:1997;603-609.
12. Fujimoto N., Mouri N., Iwata K., Ohuchi E., Okada Y., Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (71-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta. 221:1993;91-103.
13. Desmet V.J., Gerber M., Hoofnagle J.H., Manns M., Scheuer P.J. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology. 19:1994;1513-1520.
14. Benyon R.C., Hovell C.J., Gaca M.D., Jones E.H., Iredale J.P., Arthur M.J.P. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology. 30:1999;977-986.
15. Milani S., Herbst H., Schuppan D., Grappone C., Pellegrini G., Pinzani M.et al. Differential expression of matrix metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am. J. Pathol. 144:1994;258-537.
16. Takahara T., Furui K., Yata Y., Jin B., Zhang L.P., Nambu S.et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology. 26:1997;1521-1529.
17. Lichtinghagen R., Michels D., Haberkorn C.I., Arndt B., Bahr M., Flemming P.et al. Matrix metalloproteinase (MMP-2), MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J. Hepatol. 34:2001;239-247.
18. Iredale J.P. Tissue inhibitors of metalloproteinases in liver fibrosis. Int. Biochem. Cell. Biol. 29:1997;43-54.
19. Murawaki Y., Ikuta Y., Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin. Chem. Acta. 281:1999;109-120.
20. Dudas J., Kovalszky I., Gallai M., Nagy J.O., Schaff Z., Knittel T.et al. Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am. J. Clin. Pathol. 115:2001;725-735.